Head of Nephrology, Department of Medicine, Division of Nephrology and Director

Education in Medicine at the Universities of Ferrara (Italy), Berlin and Würzburg

Thesis (degree of M.D.) at the University of Würzburg, Department of Medicine

Residency and Fellowship in Internal Medicine and Nephrology at the Department of Medicine, Division of Nephrology, University of Freiburg.

Habilitation (equivalent to PhD), Member of the Faculty.
Assistent professor, Department of Medicine, Division of Nephrology, University of Freiburg.

Professor of Medicine, Department of Medicine, Division of
Nephrology, University of Wuerzburg

1990-

Role of lipids in the progression of renal disease; glomerulosclerosis, atherosclerosis in kidney failure patients; 1998-2005. Principal investigator of the 4D study, a major clinical trial in diabetic patients on dialysis. 2003- : Central Europe Coordinator of SHARP (study of heart and renal protection)

Elucidation of the inflammatory response syndrome in diabetic nephropathy, chronic kidney disease and kidney failure

Functional genomics of cardiovascular disease. DNA studies in 4D index patients and family members (genetic field working).

President, German Kidney Foundation

Vice-Chairman, German Association of Clinical Nephrology

Int Soc Nutrition & Metabolism in Renal Disease

1995-2000   Nephrology Dialysis Transplantation (Editorial Board)

1997-2002   Kidney & Blood Pressure Research (Editorial Board)

2002-2004   American Journal Kidney Disease (Associate Editor)

2000-present      Subject Editor: Nephrology Dialysis Transplantation

2002-present      Editorial Board: Nephron

2003-present      Editorial Board: Journal of Renal Nutrition

2005-present      Editorial Board: Port J of Nephrology

2006-present      Editorial Board: Current Opinion in Nephrology & Hypertension

2006-present      Editorial Board: Folia Biologica – J Cell Mol Biol

2003-present      Editor-in-chief: Kidney & Blood Pressure Research

ADVISORY AND REVIEW ACTIVITIES:

1994-                Deutsche Forschungsgemeinschaft (DfG), BMBF - Human genome project,

2000-2006:       European best practice guidelines – hemodialysis (Part I &II), active member and advisory board of the ERA-EDTA-Registry

2000-2006:       K/DOQI,  Kidney Dialysis Oualitative Initiative: Clinical practice guidelines on managing dyslipidemias in CK work group / Guidelines on prevention of diabetic nephropathy

2003-2006:       KDIGO, Kidney Disease improving Global Outcome - Board of Directors

2003-2009:       Member, ERA-EDTA Registry

2007-present:  KDIGO - Board of Councilors

INTERNATIONAL EDUCATION AND TEACHING:

2000-2007:      Courses on “How to write a paper” – “How to read and review a paper” (World Congress of Nephrology Berlin, Oxford/UK, Austria/Innsbruck-Salzburg)

2002-2007:       Lecturer - Junior Scientific Masterclass - Introduction to Medical Research / Mannheim Faculty of Medicine

2004-2007:       Lecturer: ERA-EDTA: Introductory Course on Epidemiology (Rome, Toledo, Thessaloniki, Stockholm) – Observational studies

2006                 Lecturer – ERA-EDTA: How To Design a Clinical Trial?

2006-2007:       Lecturer - American Society Nephrology: Course - Applying the Principles of Epidemiology and Biostatistics: Randomized Controlled  Trials: Good as Gold

1985: Award for Clinical Investigation, American Medical Association

1991: Merck Award for Clinical Investigation – Hypertension

2006: Official Visiting Professor of the Faculty of Medicine, Charles University of
           Prague

2007: Annals Internal Medicine: top ten reviewer 2007

2007: International Distinguished Medal of the US National Kidney Foundation

• Vth International Congress of Uraemic Toxicity (2002)

• 130 original, peer review publications (244 in pubmed): Am J Physiol, Am J Transplantation, Ann Intern Med, Am J Clin Nutr, Brit J Pharmacol, Circulation, FASEB J, Hypertension, J Am Soc Nephrol, Lancet, New Engl J Med

• 190 reviews and editorials

• 40 books and book chapters

• Guest Editor: Kidney International 2003, Clin Therapeutics 2007

Schwedler S, Schinzel R, Metzger T, Wanner C. Advanced glycation end products and mortality in hemodialysis patients. Kidney Int 2002;62:301-310

Stenvinkel P, Wanner C, Metzger T, Heimbürger O, Mallamaci F, Tripepi G, Malatino L, Zoccali C. Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage? Kidney Int 2002;62:1791-1798

Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Böhm R, Metzger T, Wanner C, Jahnen-Dechent W, Floege J. Cardiovascular mortality in dialysis patiens. Low Ahsg/Fetuin serum levels may be a critical factor. Lancet 2003;361:827-833

Galle J, Mameghani A, Bolz SS, Gambaryan S, Görg M, Quaschning T, Raff U, Barth H, Seibold S, Wanner C, Pohl U. Oxidized LDL and its compoiund lysophosphatidylcholine potentiate AngII-induced vasoconstriction by stimulation of RhoA. J Am Soc Nephrol 2003;14:1471-1479

Seibold S, Rudroff C, Weber M, Galle J, Wanner C, Marx M. Identification of a new tumor suppressor gene located at chromosome 8p21.3-22. FASEB J 2003;17:1180-1182

Wanner C, Krane V, März W, Olschewski M, Asmus H-G, Krämer W, Kühn K-W, Kütemeyer H, Mann J, Ruf G, Ritz E for the Deutsche Diabetes Dialyse Studie (4D) Study group (see appendix). Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D Study): demographic and baseline characteristics. Kidney Blood Press Res 2004;27:259-266

Schwedler SB, Amann K, Wernicke K, Krebs A, Nauck M, Wanner C, Potempa LA, Galle J. Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout mice. Circulation 2005; 112:1016-1923

Wanner C, Krane V, März W, Olschewski M, Mann JFE, Ruf G, Ritz E for the German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New Engl J Med 2005;353:238-248